• SPX
  • $5,544.59
  • -0.78 %
  • -$43.68
  • DJI
  • $40,665.02
  • -1.29 %
  • -$533.08
  • N225
  • $40,077.15
  • -0.12 %
  • -$48.98
  • FTSE
  • $8,204.89
  • 0.21 %
  • $17.43
  • IXIC
  • $17,871.22
  • -0.7 %
  • -$125.70

Wave Life Sciences Ltd. (WVE) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.74

-$0.17

(-2.88%)

Day's range
$5.69
$6
52 wk range
$3.5
$7.67
50-day range
$4.25
$6.63
  • Country: SG
  • ISIN: SG9999014716
WVE Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -4.61
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (WVE)
  • Company Wave Life Sciences Ltd.
  • Price $5.74
  • Changes Percentage (-2.88%)
  • Change -$0.17
  • Day Low $5.69
  • Day High $6.00
  • Year High $7.67

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/01/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $14.00
  • High Stock Price Target $17.00
  • Low Stock Price Target $11.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.51
  • Trailing P/E Ratio -11.39
  • Forward P/E Ratio -11.39
  • P/E Growth -11.39
  • Net Income $-57,513,000

Income Statement

Quarterly

Annual

Latest news of WVE

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In


or

Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.